Telprez Plus, tablets 80 mg+12, 5 mg 98 pcs

Hypertension (high blood pressure)Arterial hypertension (if telmisartan or hydrochlorothiazide is ineffective in monotherapy).

Indications

Arterial hypertension (in case of ineffectiveness of telmisartan or hydrochlorothiazide in monotherapy).

Pharmacological effect

Pharmacotherapeutic group:

Special instructions

Liver dysfunction

Active ingredient

Hydrochlorothiazide, Telmisartan

Composition

Each 12.5 mg + 80 mg tablet contains:

Contraindications

– Hypersensitivity to the active substances or auxiliary components of the drug or other sulfonamide derivatives;
– Pregnancy;
– Breastfeeding period;
– Obstructive diseases of the biliary tract;
– Severe liver dysfunction (class C according to the Child-Pugh classification);
– Severe renal dysfunction (creatinine clearance less than 30 ml/min);
– Refractory hypokalemia, hypercalcemia;
– Concomitant use with aliskiren in patients with diabetes mellitus and/or impaired renal function (glomerular filtration rate less than 60 ml/min/1.73 m2);
– Concomitant use of ACE inhibitors in patients with diabetic nephropathy;
– Lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome;
– Age up to 18 years (efficacy and safety have not been established).
With caution:
– Bilateral renal artery stenosis or stenosis of the artery of a single kidney (see section “Special instructions”);
– Liver dysfunction (class A and B according to the Child-Pugh classification) (see section “Special instructions”);
– Decrease in blood volume due to previous diuretic therapy, restriction of salt intake, diarrhea or vomiting;
– Hyperkalemia;
– Condition after kidney transplantation (no experience of use);
– Chronic heart failure III-IV functional class (FC) according to the New York Heart Association classification;
– Hypercalcemia;
– Hypercholesterolemia;
– Hypertriglyceridemia;
– Coronary heart disease;
– Progressive liver diseases (risk of developing hepatic coma);
– Stenosis of the aortic and mitral valve;
– Idiopathic hypertrophic subaortic stenosis (hypertrophic obstructive cardiomyopathy);
– Diabetes mellitus;
– Primary hyperaldosteronism;
– Gout, hyperuricemia;
– Systemic lupus erythematosus;
– Secondary angle-closure glaucoma (due to the presence of hydrochlorothiazide in the composition);
– Use in patients of the Negroid race;
– Experience in patients with renal impairment (creatinine clearance more than 30 ml/min) is limited, but does not confirm the development of side effects from the kidneys and dose adjustment is not required;
– Concomitant use with ACE inhibitors or aliskiren;
– Simultaneous use with potassium preparations, potassium-sparing diuretics.

Side Effects

1) expected based on experience with telmisartan
2) expected based on experience with hydrochlorothiazide
3) side effects that were not observed in clinical studies with the simultaneous use of telmisartan and hydrochlorothiazide, but are expected during the use of Telpres Plus

Interaction

Telmisartan
Telmisartan may increase the antihypertensive effect of other antihypertensive agents. Other types of interactions of clinical significance have not been identified.

Overdose

Information regarding overdose is limited. Possible symptoms of overdose consist of symptoms from the individual components of the drug. Telmisartan – the most significant – a pronounced decrease in blood pressure and tachycardia, bradycardia, dizziness, an increase in serum creatinine concentration and acute renal failure may also be observed.

Storage conditions

At a temperature not exceeding 25 °C, in the original packaging.

Shelf life

2 years.

Manufacturer

Laboratorios Likonsa S.A., Spain